GPCR信号偏差:一种新兴的阿片类药物开发框架
1Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan.
Journal of biochemistry
|February 2, 2024
概括
在G蛋白合受体 (GPCRs) 中偏差信号提供了一条通往更安全的药物的途径. 本综述探讨了偏见的阿片类受体信号传递,以开发具有较少副作用的有效止痛药.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 偏差信号或功能选择性对于开发更安全的针对G蛋白结合受体 (GPCRs) 的药物至关重要.
- 片类止痛药虽然有效缓解疼痛,但会引起严重的副作用,需要更安全的替代品.
- 了解G蛋白和β-arrestin (βarr) 信号之间的平衡对于开发新型疼痛药物至关重要.
研究的目的:
- 提供阿片类受体中偏差信号的概述,重点关注μ-阿片类受体 (MOR).
- 描述在GPCR领域评估信号偏差的方法.
- 通过使用集成信号数据,讨论未来合理药物开发战略.
主要方法:
- 关于GPCRs和阿片类受体中偏差信号的当前文献的综述.
- 讨论基于蛋白质-蛋白质相互作用的方法来分析个体信号通路.
- 对G蛋白和β-arrestin (βarr) 信号传递动态的分析.
主要成果:
- 偏差信号提供了一个机会,可以提高治疗疗效,同时最大限度地减少针对GPCR药物的副作用.
- 新的蛋白质-蛋白质相互作用方法可以精确评估单个信号通路.
- 了解MOR信号的平衡是开发更安全的止痛药的关键.
结论:
- 开发更安全的阿片类止痛药需要对偏差信号的深入理解.
- 整合多样化的信号数据集可以指导合理的药物设计,以改善治疗结果.
- 未来的研究应该专注于利用偏差信号来创建具有减少副作用概况的有效止痛药.
相关概念视频
01:22Opioid Receptors: Overview
836
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
836
01:25Analgesia and Pain Management
623
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
623
01:12GPCR Desensitization
6.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.0K
01:26Drug Discovery: Overview
7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
01:30Transducer Mechanism: G Protein–Coupled Receptors
2.0K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.0K